Previous Article | Next Article 
Infection and Immunity, November 1998, p. 5372-5378, Vol. 66, No. 11
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Mechanisms Involved in the Pathogenesis of Sepsis
Are Not Necessarily Reflected by In Vitro Cell Activation
Studies
Claudia R.
Amura,1,
R.
Silverstein,2 and
D. C.
Morrison1,3,*
Department of Microbiology, Molecular Genetics and
Immunology,1
Department of Biochemistry
and Molecular Biology,2 and
The
Kansas Cancer Institute,3 The University of
Kansas Medical Center, Kansas City, Kansas 66160
Received 30 December 1997/Returned for modification 10 March
1998/Accepted 20 August 1998
 |
ABSTRACT |
It is thought that lipopolysaccharide (LPS) from gram-negative
bacteria contributes significantly to the pathogenesis of septic shock.
In vitro studies to address the mechanisms involved in this process
have often investigated human monocytes or mouse macrophages, since
these cells produce many of the mediators found in septic patients.
Targeting of these mediators, especially tumor necrosis factor alpha
(TNF-
), has been pursued as a means of reducing mortality in sepsis.
Two experimental approaches were designed to test the assumption that
in vitro studies with macrophages accurately predict in vivo mechanisms
of LPS pathogenesis. In the first approach, advantage was taken of the
fact that on consecutive days after injection of thioglycolate into
mice, increased numbers of macrophages could be harvested from the
peritoneum. These cells manifested markedly enhanced levels of in vitro
TNF-
, interleukin 6 (IL-6), and nitric oxide production in response
to LPS. In D-galactosamine-sensitized mice, however,
thioglycolate treatment significantly decreased mortality due to LPS,
as well as levels of circulating TNF-
and IL-6. Anti-TNF-
treatment confirmed this cytokine's role in the observed lethality. In
a second experimental approach, we compared the mouse
macrophage-stimulating potencies of different LPS preparations with
their lethalities to mice. In these studies, the in vitro macrophage-stimulating profiles presented by rough-LPS and smooth-LPS preparations were the reverse of their relative lethal potencies in
vivo. In conclusion, peritoneal macrophages appear not to be the major
cells responsible for the overall host response during endotoxic shock.
These findings underscore the importance of verifying the
correlation of in vivo systems with in vitro systems when attributing
specific functions to a cell type.
 |
INTRODUCTION |
Infections caused by gram-negative
bacteria constitute one of the major causes of the sepsis syndrome,
characterized by hypotension, tachycardia, tachypnea, disseminated
intravascular coagulation, and multiple organ system failure. The
mortality rate for septic shock patients continues to be unacceptably
high, in spite of therapeutic intervention and rigorous supportive care
(5, 23). In the last several years, many studies have
focused on efforts to define the pathogenic mechanisms responsible for
the inflammatory response that results in the sepsis syndrome. Many
laboratories have contributed to the development of the concept that
lipopolysaccharide (LPS), a major constituent of the outer cell
membrane in gram-negative bacteria, is an important contributing factor
to the pathogenesis of the sepsis syndrome. In this respect, it has
been established that the administration of LPS to experimental animals
or human volunteers will reproduce many of the proinflammatory and
pathophysiological responses seen in patients with septic shock
(7, 29).
Both human monocytes and mouse macrophages have been extensively
utilized as prototypic cells involved in the pathogenesis of sepsis in
vitro. Most studies have shown that the interaction of LPS with these
cells induces the release of several cytokines, including tumor
necrosis factor (TNF), interleukin 1 (IL-1), IL-6, IL-8, and gamma
interferon (IFN-
), as well as other inflammatory mediators such as
prostaglandins, leukotrienes, platelet activation factor, and nitrogen
and oxygen intermediates. Most of these immunological mediators present
multiple biologic effects, play a critical role in inflammation and
immune responses, and have been recognized as key mediators in the
pathogenesis of infectious diseases and, more particularly, the
pathophysiologic alterations observed in endotoxic shock (6, 26,
30, 37, 40, 41, 43). Potential roles for TNF-
, IL-1, IL-4,
IL-6, IL-8, IL-10, and IFN-
have been suggested by the results of in
vivo studies of bacteremia and septic shock caused by both
gram-positive and gram-negative bacteria. Also, those studies have
provided evidence that immunotherapeutic intervention strategies that
abrogate the biological activities of many of these mediators can have
a significant protective effect against the lethal effects of LPS
(4, 12, 16).
Over the past years, a number of laboratories investigating the events
leading to endotoxic shock have pointed to TNF-
as a main mediator
of the sepsis syndrome, as evidenced by an increase of this cytokine
upon LPS administration to experimental animals and human volunteers,
as well as during clinical sepsis (7, 20). In experimental
animals, sensitization to the lethal effects of LPS by
D-galactosamine (D-GalN) also parallels a
marked sensitization to toxicity caused by TNF-
(14, 15),
making this model particularly amenable to study of the role of TNF-
in sepsis. Additionally, immunotherapeutic intervention to abrogate the
biological activity of TNF-
has been established as a means to
protect against the lethal effects of endotoxin in animal models but
has proven more problematic in clinical trials for the treatment of
sepsis (1, 10, 28). The information provided by all these
studies, however, remains controversial, depending on the experimental
approach being utilized, and there are clearly a number of studies that suggest strongly that TNF alone cannot fully explain the lethal effect
of LPS. In this regard, it has been reported that TNF serum levels do
not correlate with mortality (33, 36). Also, whereas treatment of mice with LPS to elicit TNF production, or with exogenous TNF, confers protection against subsequent cecal ligation and puncture
(8) or against bacterial challenge in granulocytopenic mice
(3), elimination of TNF has variable effects on survival in
cases of endotoxemia (9, 11, 32). Endotoxic LPS can also
stimulate inflammatory cells to produce other proinflammatory cytokines
that are often detected in the sera of patients with sepsis due to
gram-negative bacteria. A number of recent reports have suggested that
it is not TNF-
alone, but rather the balance of pro- versus
anti-inflammatory cytokines, that dictates the severity and lethality
of murine sepsis (17, 42).
The purpose of the studies reported here was to test the assumption
that in vitro studies to evaluate the LPS-phenotypic response of mouse
macrophages would accurately predict in vivo mechanisms of LPS
pathogenesis. Therefore, we have carried out experiments in vitro to
assess macrophage responses to LPS, and in parallel, we have used a
mouse model of hypersensitivity to LPS induced by D-GalN
treatment to assess in vivo lethality. Our experiments have
demonstrated that macrophages harvested from the peritoneum on
consecutive days after the injection of thioglycolate manifested temporally enhanced in vitro production of TNF-
, IL-6, and nitric oxide in response to LPS. In the in vivo mouse model of
D-GalN-induced sensitization to LPS, however, thioglycolate
treatment induced a significant decrease in mortality due to LPS, as
well as in levels of circulating TNF-
and IL-6. The central role of
TNF-
in the observed lethality was, nevertheless, confirmed by
treatment of mice with anti-TNF-
antibody (Ab). As an alternative
method to explore the question, we have used normal and
D-GalN-treated mice that have been administered various
doses of two LPS preparations known to differ significantly in their
capacities to induce TNF-
production in mouse macrophages in vitro.
Our results support the idea that mouse peritoneal macrophages are not
major contributors to the host cytokine responses during
endotoxin-induced injury in vivo. These results underscore the
importance of verifying potential correlations of in vivo systems with
in vitro systems when attributing specific functions to a given cell
type.
 |
MATERIALS AND METHODS |
Animals.
Female C3HeB/FeJ mice, 6 to 10 weeks of age, were
purchased from Jackson Laboratories (Bar Harbor, Maine), housed for at
least 1 week in laminar-flow isolation units in the Kansas University Medical Center vivarium (which is accredited by the American
Association for Accreditation of Laboratory Animal Use) under alternate
dark-light cycles, and fed pellet chow ad libitum.
Reagents.
R60 (Ra) rough LPS from Salmonella
minnesota (R-LPS) or smooth LPS from Escherichia coli
0111:B4 (S-LPS), containing less than 1.5% protein (wt/wt), were
purchased from List Biological Laboratories (Campbell, Calif.). The LPS
preparations were solubilized in pyrogen-free, sterile, distilled
H2O to make stock solutions of 1 mg/ml. The stock solutions
were sonicated for 3 min (W385 sonicator; Heat System Ultrasonic Inc.,
Farmingdale, N.Y.) and appropriately diluted immediately before use.
D-GalN (Sigma Chemical Co., St. Louis, Mo.) sodium salts
were freshly prepared in phosphate-buffered saline (PBS) just prior to
use. Brewer thioglycolate, containing less than 0.1 endotoxin unit of
LPS, as determined by a Limulus amebocyte assay, was
purchased from Difco Laboratories, Detroit, Mich.
In vivo lethality studies.
Groups of mice were injected via
the intraperitoneal route with various doses of LPS. For the
D-GalN sensitization model, mice were injected with 0.4 ml
of a solution of 20 mg of D-GalN in PBS/25 g of body
weight, or with an equivalent volume of vehicle, containing increasing
amounts of LPS. Some mice were injected with thioglycolate 5 days prior
to the LPS challenge, as previously described. Mortality was assessed
after 14 h of LPS administration in the D-GalN model,
or after 48 h in the normal mouse model, as described previously
(38). For the analysis of cytokines in serum, mice were bled
via retro-orbital sinus puncture at 1 and 4 h after LPS injection.
When mice were passively immunized against TNF-
, 6.75 × 104 neutralizing units of anti-TNF-
Ab (the kind gift of
Roderick McCallum) per mouse was injected via the intraperitoneal route 4 h prior to endotoxin challenge, as described previously
(21).
Macrophage isolation and stimulation.
Exudate macrophages
were obtained by peritoneal lavage with 10 ml of sterile culture medium
on consecutive days after intraperitoneal injection of 1.5 ml of 4%
Brewer thioglycolate. Viability and total cell counts were assessed by
staining with trypan blue. Differential counts were performed on
cytospins stained with Diff-Quick solution. Total cells were suspended
in RPMI 1640 medium containing 0.3% NaHCO3 (Sigma Chemical
Co.), 2 mM glutamine, 100 U of penicillin/ml, and 100 µg of
streptomycin/ml (JRH Biosciences, Lenexa, Kans.) and seeded at 0.5 × 106 to 2 × 106 macrophages/well (in
24- or 6-well culture plates; Costar, Cambridge, Mass.). After 2 to
3 h of incubation at 37°C and 5% CO2, nonadherent cells were removed by two washes with culture medium, and adherent cells were stimulated with the indicated concentrations of LPS. Following incubation at 37°C in 5% CO2 for 18 h,
culture supernatants were collected and assayed for TNF-
and IL-6 as
described below (2). Cell attachment was assessed by
staining of total versus adherent cells with
3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl-tetrazolium bromide (MTT;
Sigma). Absorbance at 570 nm (A570) was measured with an MR5000 microplate reader (Dynatech Laboratories, Chantilly, Va.). Alternatively, total numbers of cells previous to and after adhesion were quantitated with a cell counter (2M; Coulter Electronics, Ltd., Hialeah, Fla.) after cell lysis and nuclear release.
TNF-
bioassay.
The amount of TNF-
present in culture
supernatants was quantified by assessing the extent of killing of the
murine cell line L929 (2, 45). Briefly, cells were seeded
into 96-well plates at 4 × 105/well in RPMI 1640 complete medium supplemented with a 10% fetal bovine serum-derived
product (FCS; HyClone Laboratories, Logan, Utah). After overnight
incubation at 37°C in 5% CO2, new medium containing 5 µg of actinomycin D (Merck & Co., West Point, Pa.)/ml was used to
replace the original medium. After an additional 2 h of
incubation, macrophage culture supernatants were added to triplicate
wells and serially diluted. The viability of L929 cells at 18 h
was determined by the MTT incorporation assay as described above.
TNF-
amounts were calculated by comparison with a recombinant mouse
TNF-
(Genzyme, Cambridge, Mass.) standard assayed in each plate.
TNF-
levels in plasma were also determined, by an enzyme-linked immunosorbent assay (ELISA) protocol described below for IL-6, by using
anti-TNF-
Abs from Pharmingen (San Diego, Calif.).
IL-6 determination.
The presence of IL-6 amounts in
macrophage culture supernatants was determined by ELISA (2,
45). Briefly, 96-well Immulon 1 microtiter plates (Dynatech) were
coated overnight at 4°C with 100 µl of a 1-µg/ml solution of rat
anti-mouse IL-6 monoclonal Ab (MAb; Pharmingen)/well. After the plates
were washed and blocked for 2 h with 200 µl of PBS-10%
FCS/well, samples or standard (recombinant mouse IL-6, 5 µg/ml;
Genzyme) in PBS-10% FCS was added in triplicate and diluted into the
plates, which were further incubated for 2 h at 37°C. After
being washed again, plates were incubated for 45 min with 100 µl of
biotinylated anti-IL-6 MAb (1 µg/ml in PBS-10% FCS)/well.
Plates were washed, and 100 µl of avidin-peroxidase conjugate
(Pierce, Rockford, Ill.)/well was added. After 30 min of incubation and
a wash, 100 µl of 3,3',5,5'-tetramethylbenzidine (TMB)-peroxidase substrate system (1:1; Kirkegaard & Perry
Laboratories, Gaithersburg, Md.) was added. The reaction was terminated
by the addition of 100 µl of 1 M phosphoric acid/well, and
A450 was determined with a Dynatech MR5000
reader.
Analysis of NO.
NO production in culture supernatants was
assessed by measuring the amount of nitrite, a metabolic product of NO
(2, 45). Briefly, supernatants in triplicate were mixed 1:1
with Griess reagent [0.1%
N-(1-naphthyl)ethylenediamine dihydrochloride-1% sulfanilamide in 5% H2PO4 (1:1, vol/vol);
Sigma] in 96-well microtiter plates, and A570
was measured with a Dynatech MR5000 microplate reader.
Statistical analysis.
Data from in vitro experiments are
expressed as means and compared statistically by Student's
t test. Mortality data were analyzed by Fisher's exact
test. Cumulative data and 50% lethal doses (LD50) were
determined according to the method of Reed and Muench (31).
Levels of significance were determined by using the Epistat statistical
package (T. Gustafson, Round Rock, Tex.) or Sigmaplot software (Jandel
Co., San Rafael, Calif.) with a personal computer. P values
less than 0.05 were considered statistically significant.
 |
RESULTS |
Differential activation of macrophages at different days after
thioglycolate injection.
Mouse macrophages exposed to LPS in vitro
demonstrate differential functional responses. In order to evaluate the
in vitro response of host cells to LPS, we compared the production of
TNF-
, nitric oxide, and IL-6 by mouse macrophages isolated from the peritoneal cavities of mice at different times following the injection of the inflammatory stimulus thioglycolate. As expected, the number of
macrophages that could be harvested from the peritoneum increased with
the number of days after thioglycolate injection. As shown by the data
in Table 1, after 5 days of exposure to
thioglycolate, the yield of total cells, as well as that of total
macrophages, from the mouse peritoneum had increased by almost 1 order
of magnitude. Also, as revealed by differential staining, the
macrophages presented more characteristics of activation, such as
increased volume, shape changes, and "foaming," at increasing
days after thioglycolate injection (data not shown). In addition to the
increase in cell number, those macrophages harvested from the
peritoneum on consecutive days after thioglycolate injection showed
markedly increased levels of in vitro TNF-
production upon
activation with R-LPS (Fig. 1). As can
readily be observed from the data presented in Fig. 2, the same degree of significant
enhancement by thioglycolate of activation with R-LPS at day 5 posttreatment was observed when IL-6 and nitric oxide were analyzed in
the same cell culture supernatants.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Time course of the effects of intraperitoneal treatment
with thioglycolate on the numbers of cells harvested from the
peritoneal cavity in micea
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
LPS-stimulated TNF- production by mouse macrophages
harvested at different days after thioglycolate (TG) injection.
Peritoneal exudate was harvested at various times following
thioglycolate administration and treated in vitro with increasing
concentrations of R-LPS. Supernatants were assessed for the presence of
TNF- after 18 h. TNF- was quantitated as the extent of
cytotoxicity for the fibroblast cell line L929 as described in
Materials and Methods. Results represent averages of triplicate
determinations ± standard errors of the means (SEM) from one
representative experiment, repeated four times under equivalent
conditions. *, P < 0.05 (by Student's t
test) with respect to the group treated with LPS alone.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Effects of thioglycolate on mediator secretion by
LPS-stimulated mouse macrophages. Cells were harvested at 0 (resident)
or 5 (TG) days after thioglycolate injection. TNF- (A), IL-6 (B),
and nitric oxide (C) production after 18 h of R-LPS stimulation
was analyzed in supernatants as described in Materials and Methods.
*, P < 0.05 (by Student's t test) in
comparison to the day 0 group.
|
|
LPS-induced mortality in thioglycolate-pretreated mice.
In
order to determine if there was a correlation between the in vitro
observations of R-LPS-induced TNF-
production by peritoneal macrophages and in vivo induction of circulating levels of TNF-
, we
used the model of D-GalN sensitization to LPS. This
experimental model has been extensively investigated as a sensitive
means by which to assess the toxic effects of TNF-
(14,
15). Therefore, the extent of contribution to lethality of an
increase in TNF-
production by peritoneal cells from mice pretreated
with thioglycolate might then be reflected in a differential increment
of sensitivity to LPS in this D-GalN model. For these
studies, therefore, either thioglycolate or sterile saline was
administered to mice via the intraperitoneal route. Five days later,
all mice were given D-GalN and increasing doses of R-LPS.
The mortality of the animals was then recorded after LPS challenge, and
the results are depicted in Fig. 3. As
previously demonstrated by Galanos et al. (14, 15), the
administration of otherwise nonlethal nanogram quantities of LPS
together with D-GalN induced high mortality rates after 12 to 14 h of challenge in both groups of animals. No further mortality was detected over a period of 48 h. In contrast to the expected results, however, the administration of thioglycolate 5 days
earlier actually diminished, rather than enhanced, the rate of
mortality induced by R-LPS in the same model of D-GalN sensitization.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 3.
LPS-induced mortality in thioglycolate (TG)-pretreated
mice. Mice were pretreated either with thioglycolate or with saline.
Five days later, all animals received graded doses of R-LPS and 20 mg
of D-GalN/g of body weight. Lethality was recorded 14 h after R-LPS challenge in D-GalN-sensitized mice.
Cumulative data were depicted according to Reed and Muench's method
(31). *, statistically significant (P < 0.05 by Fisher's exact test) compared with the respective R-LPS dose
in thioglycolate-treated animals. The number of mice in each group is
given in parentheses.
|
|
Circulating cytokines induced by LPS in thioglycolate-pretreated
animals.
By using the same mouse model of sensitization to LPS and
TNF-
, the next series of experiments was performed in order to determine the actual level of production of TNF-
in vivo. The presence of this cytokine was therefore assessed in serum collected 1.5 or 4 h after R-LPS challenge from mice treated with thioglycolate or with saline as a control 5 days previously. As can be seen from the
data depicted in Fig. 4A, the
administration of R-LPS induced readily detectable circulating levels
of TNF-
above background at 1.5 h post-LPS administration. The
levels of TNF-
were significantly decreased in all animals at 4 h compared to the 1.5-h levels (data not shown). In contrast to what
might be expected from the in vitro data, however, but in accordance
with the data presented in Fig. 3, mice pretreated with thioglycolate
manifested lower levels of TNF-
in circulation in response to R-LPS
challenge than mice pretreated with sterile saline. Additionally, the
levels of IL-6 in circulation showed patterns similar to those observed for TNF-
(Fig. 4B).

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 4.
Effects of thioglycolate (TG) pretreatment on
circulating TNF- (A) or IL-6 (B) levels induced by LPS in
D-GalN-sensitized mice. Mice were treated as described in
the text, and cytokine levels in serum collected 1.5 h after R-LPS
challenge were determined by ELISA. Cytokine levels in sera collected
4 h after stimulation were below the detection limit. Results from
one representative experiment, repeated five times, are depicted.
|
|
These data would indicate that there is a correlation between the
ability of LPS to induce TNF-

in vivo and lethality. In
fact, when
circulating levels of TNF-

and IL-6 at 1.5 h induced
by R-LPS
(Fig.
4) were analyzed as functions of lethality (Fig.
3), high degrees
of correlation were obtained (
r = 0.79 and
r = 0.68, respectively), both in animals treated with
thioglycolate
and in those given saline. However, this correlation does
not
extend to the ability of peritoneal macrophages to respond in
vitro
to LPS stimulation by producing this cytokine (compare with
Fig.
2).
Effect of targeting TNF-
as a means to decrease LPS-induced
mortality in thioglycolate-pretreated mice.
Efforts to decrease
the mortality induced by LPS by targeting some of the mediators thought
to be involved in shock, such as TNF-
, have been attempted in a
number of published studies. Therefore, in the next series of
experiments, we administered TNF-
-neutralizing Abs in the
D-GalN model of sensitization to LPS. We anticipated that
if, in fact, less total TNF-
was being generated in the
thioglycolate-pretreated animals, then less anti-TNF-
Ab should be
required to provide protection. As shown by the data in Fig.
5, the administration of increasing doses
of anti-TNF-
Ab significantly decreased the mortality rates induced
by 5 µg of R-LPS/kg in both saline- and thioglycolate-pretreated
D-GalN-sensitized mice. Of interest, and as predicted,
animals pretreated with thioglycolate required significantly less
TNF-
-neutralizing Ab to decrease mortality rates than did control,
saline-treated mice.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 5.
Effects of anti-TNF- Ab treatment on LPS-induced
mortality in thioglycolate (TG)- versus saline-pretreated,
D-GalN-sensitized mice (n = 8 per group).
Various amounts of anti-TNF- neutralizing Abs were administered to
mice 3 h before the administration of D-GalN plus
R-LPS (5 µg/kg). Mortality was recorded after 14 h, and
cumulative data were depicted according to the method described by Reed
and Muench (31). *, P < 0.05 (by
Fisher's exact test).
|
|
Using the same protocol, we further investigated the effects of
administering anti-TNF-

Ab on cytokine production induced
by LPS in
vivo (Fig.
6). As has been previously
demonstrated,
the administration of 5 µg of R-LPS/kg induced the
synthesis of
levels of both TNF-

and IL-6 that were readily
detectable in
circulation at 1.5 h. Also as previously shown (Fig.
4), treatment
of the animals with thioglycolate 5 days previously
diminished
their abilities to produce IL-6 and TNF-

in response to
LPS.
The administration of anti-TNF-

neutralizing Ab prior to the
LPS challenge abrogated the detection of TNF-

in circulation
and
significantly diminished the production of IL-6 in vivo. The
latter
finding should not be totally surprising, given the enhancing
role that
TNF-

plays in secretion (
34). As was found earlier
in the
mortality studies, the doses of anti-TNF-

neutralizing
Ab required
to diminish the production of both cytokines were
lower in animals
previously treated with thioglycolate than in
control mice.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of anti TNF- Ab on TNF- and IL-6 production
induced by LPS in D-GalN-sensitized mice pretreated with
thioglycolate (TG) or saline (control). Mice were treated as described
in the text, and cytokine levels in serum were evaluated by ELISA.
Results from one representative experiment, repeated five times with
similar results, are depicted.
|
|
Differential mortality induced by different preparations of LPS in
normal versus D-GalN-sensitized mice.
Published
reports from a number of laboratories, including studies from our own
laboratory, have clearly shown that different preparations of LPS can
induce different cytokine responses in macrophages in vitro. In this
respect, for example, results from our laboratory have shown that S-LPS
from E. coli was significantly less active in stimulating
macrophages to produce TNF-
than R-LPS from S. minnesota
(Fig. 7A, partially reproduced from
reference 45). This observation, therefore, provides
an alternative approach to testing whether the differences observed in
assays of the in vitro response of peritoneal macrophages to LPS can
accurately reflect in vivo LPS-mediated mortality. Therefore, we
compared the mortality rates induced in mice by these two preparations of R- and S-chemotype LPS in order to test directly the concept that an
increased level of TNF-
production in vitro induced by R-LPS in
comparison to S-LPS should be reflected by higher sensitivity to R-LPS
than to S-LPS in the D-GalN sensitization model in vivo. The lethal effects of both LPS chemotypes were then analyzed, and the
mortality results after challenge are depicted in Fig. 7B. Contrary to
what might be expected from the in vitro data presented in Fig. 7A, the
LD50 of S-LPS was approximately sixfold lower than that of
R-LPS (Fig. 7B, left panel). In normal mice, however, the two
chemotypes of LPS induced virtually indistinguishable levels of
mortality as functions of the LPS dose (Fig. 7B, right panel). Of
interest, however, even though the LD50 were superimposable in normal mice (Fig. 7B, right panel), the temporal profile of lethality response induced by R-LPS was significantly delayed with
respect to that induced by S-LPS (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 7.
(A) In vitro TNF- response induced by S-LPS or R-LPS
(Ra-LPS) in peritoneal-exudate macrophages. TNF- was quantitated by
cytotoxicity toward L929 cells, as described above. Results are
averages of triplicate determinations ± SEM from one
representative experiment (partially reproduced from reference
45) with permission of the publisher). (B) (Left)
Mortality rates induced by different preparations of LPS (S-LPS and
Ra-LPS) in D-GalN-sensitized mice. Animal mortality was
recorded 14 h after challenge, and cumulative data were depicted
according to the method described by Reed and Muench (31).
*, P < 0.05 by Fisher's exact test. (Right)
Mortality rates induced by S-LPS and Ra-LPS in normal mice, 24 h
after LPS challenge.
|
|
 |
DISCUSSION |
Over the last several decades, many laboratories have carried out
experiments designed to elucidate the mechanisms involved in the
activation of host cells induced by LPS during inflammatory processes.
A number of these studies have contributed to the identification of a
series of proinflammatory mediators that have been proposed as key
effector molecules in the pathogenesis of septic shock. TNF-
is now
thought to play a major role in several, but not all, experimental
models of sepsis, including LPS lethality in mice. Here we report
several experimental approaches that have been designed to evaluate the
participation of LPS-induced TNF-
produced by macrophages in the
development and pathogenesis of septic shock.
Surprisingly, our results have demonstrated a potential lack of
correlation between results obtained from in vitro experiments and
those obtained from in vivo experiments. We initially observed that
exudate macrophages isolated from the peritoneums of
thioglycolate-treated mice showed a significantly increased capacity to
produce TNF-
, IL-6, and nitric oxide in response to LPS in
comparison to resident macrophages. It has been observed previously
that thioglycolate-elicited macrophages could produce larger amounts of
lymphocyte-activating factor than resident cells (34). It
could be hypothesized that the difference observed between elicited and
resident macrophages could be due to different cell compositions. Even
when an increased proportion of macrophages could be obtained at
increasing days after thioglycolate injection, this difference could
not account for the differences observed in cell response. This
observation that resident macrophages are not as responsive to LPS for
the production of these inflammatory mediators as
thioglycolate-elicited macrophages could be confirmed by a recent
report showing that resident macrophage responsiveness is, in part,
induced by adherence to plastic (22). In this respect, the
fact that resident exudate cells showed a lower level of adherence to
the plastic, due to a higher proportion of lymphocytes, could not
account for the decrease of several orders of magnitude in the response
to LPS in comparison with elicited macrophages. Opposite results,
however, were observed in our D-GalN sensitization model,
in which animals became markedly more sensitive to the lethal effect of
LPS due to a higher degree of sensitivity to TNF toxicity. The results of the in vivo experiments showed a decreased mortality rate in D-GalN-sensitized animals pretreated with thioglycolate,
correlating with a decreased amount of TNF in circulation. These
results, therefore, could lead to the idea that macrophage-derived
TNF-
might not be the crucial factor contributing to death in septic shock. The participation of TNF-
, however, would appear to be significant, since our experiments for which results are shown in Fig.
2 demonstrated, in accordance with several other reports, that the
administration of Abs neutralizing TNF-
significantly diminished the
rate of mortality induced by LPS in these animals. Moreover, this
effect seems not to be specific for LPS, since it has been reported
that anti-TNF Ab also protects GalN-sensitized mice from shock induced
by staphylococcal enterotoxin B or toxic shock syndrome toxin 1 (24, 27). Thus, these data would contribute information on
the precise role of LPS-macrophage interactions as pivotal events in
the generation of TNF-
, leading to the development of the systemic
inflammatory response syndrome and septic shock.
This is not to say, however, that macrophage-derived TNF-
cannot
contribute to TNF-
-mediated lethality in the D-GalN
mouse model. In this respect, one need only consider the seminal
studies of Galanos and coworkers showing that high sensitivity to the lethal effects of LPS was achieved for D-GalN-treated mice
of the C3H/HeJ (nonresponder to LPS) strain by transfer of macrophages from the C3H/HeN (LPS responder) strain (13). Nevertheless, the more global concept that peritoneal macrophages might serve as the
primary source of cells producing TNF-
in the LPS-challenged experimental animals does not appear to be fully validated, and other
organs, such as the liver, with a high proportion of Kupffer cells,
could readily serve as likely sources of TNF-
observed in
circulation after the injection of LPS into mice (18).
Recent studies by Kumins et al. (23) showing that partial
hepatectomy reduces the level of LPS-induced circulating TNF would
certainly be supportive of such views, although some previous studies
suggested that splenic macrophages would not constitute the main source of TNF (35).
It has been described that preexposure of cells or animal to low doses
of endotoxin induces an altered pattern of mediator production in
response to a subsequent LPS challenge, a phenomenon known as endotoxin
tolerance (46). In this context, a possible explanation for
our in vivo results would be that animals exposed for several days to
the irritant stimulus thioglycolate manifested a
"desensitization"-like state when challenged with LPS, thus showing
lower levels of TNF-
secretion into the bloodstream than nonstimulated control mice. While the total levels of circulating mediators such as TNF-
participating in vivo might not necessarily be reflected by results obtained in vitro, this phenomenon would not
explain the fact that exudate macrophages did not manifest a tolerant
phenotype when examined for LPS responses in vitro. Rather, these cells
were activated towards higher in vitro responses to LPS by the
thioglycolate treatment. Also, in a completely different system
evaluated in parallel, R-LPS and S-LPS preparations manifested stimulating activities in vitro that were not reflective of their lethal potencies in vivo. Similar differences in the potencies of R-LPS
and S-LPS to induce TNF in vitro have been reported by us and others
(19, 45). However, this second example of a lack of
correlation between in vitro and in vivo activities of LPS, in which no
preliminary treatment was administered to the mice prior to LPS
challenge, would also argue against a desensitization hypothesis as
fully explaining these findings. Another possible explanation of our
findings would be that the inflammatory response elicited by the
thioglycolate contributes to an intraperitoneal accumulation of
inhibitory molecules such as soluble CD14 (sCD14) that could neutralize
LPS toxicity. It has been reported that the preadministration of sCD14
partially reduced mortality due to LPS, but it did not prevent the
shock symptoms and liver injury, nor did it affect the secretion of
proinflammatory cytokines in normal or galactosamine-sensitized mice
(39). This would be in opposition to our results, where we
have observed a decrease in levels of LPS-induced circulatory TNF-
and IL-6 in thioglycolate-pretreated mice.
In conclusion, our results suggest that peritoneal macrophages appear
not to be the major contributing cells in overall host response during
endotoxic shock. Even when this observation could be due to the systems
under evaluation, the data reported here confirm several contradictions
between the results obtained from in vitro and in vivo systems of
evaluation of LPS activation. Similarly, evidence showing that
circulating cytokine levels participating in in vivo lethality might
not necessarily parallel in vitro results has been reported recently
(44). Our findings might, therefore, allow the paradigm of
TNF-
production by peritoneal macrophages as the main event involved
in the pathogenesis of septic shock to be challenged. Finally, these
results underscore the importance of verifying the correlation of in
vivo and in vitro systems when attributing specific functions to a
specific cell type(s) and/or to a given inflammatory mediator(s).
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the National Cancer
Institute (PO1 CA54474 and R37-AI23447) and an unrestricted medical grant from Merck and Co. C.R.A. was a scholar of the Kansas Health Foundation.
We acknowledge Roderick McCallum with gratitude for his kind gift of
anti-TNF-
Ab. We thank James Goss of List Biologicals for helpful
assistance and Kathy Rode for help in the preparation of the final form
of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, 3901 Rainbow Blvd., 1000 Wahl Hall East, Kansas City,
KS 66160. Phone: (913) 588-1380. Fax: (913) 588-1388. E-mail: dmorriso{at}kumc.edu.
Present address: Immunology and Respiratory Medicine, National
Jewish Center, Denver, CO 80206.
Editor:
J. R. McGhee
 |
REFERENCES |
| 1.
|
Abraham, E.,
R. Wunderink,
H. Silverman,
T. M. Perl,
S. Nasraway,
H. Levy,
R. Bone,
R. P. Wenzel,
R. Balk,
R. Allred, et al.
1997.
Efficacy and safety of monoclonal antibodies to tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha Mab sepsis group.
JAMA
273:934-941.
|
| 2.
|
Amura, C. R.,
L. C. Chen,
N. Hirohashi,
M. G. Lei, and D. C. Morrison.
1997.
Two functionally independent pathways for the LPS-dependent activation of mouse peritoneal macrophages.
J. Immunol.
159:5079-5083[Abstract].
|
| 3.
|
Amura, C. R.,
P. A. Fontan,
N. Sanjuan, and D. O. Sordelli.
1994.
The effect of treatment with interleukin-1 and tumor necrosis factor on Pseudomonas aeruginosa lung infection in a granulocytopenic mouse model.
Clin. Immunol. Immunopathol.
73:261-266[Medline].
|
| 4.
|
Beutler, B.,
I. W. Milsark, and A. Cerami.
1985.
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin.
Science
229:869-871[Abstract/Free Full Text].
|
| 5.
|
Bone, R. C.
1991.
Sepsis syndrome. New insights into its pathogenesis and treatment.
Infect. Dis. Clin. N. Am.
5:793-805[Medline].
|
| 6.
|
Bucklin, S. E.,
S. W. Russell, and D. C. Morrison.
1994.
Participation of IFN-gamma in the pathogenesis of LPS lethality.
Prog. Clin. Biol. Res.
388:399-406[Medline].
|
| 7.
|
Cannon, J. G.
1992.
Endotoxin and cytokine responses in human volunteers, p. 312-326.
In
J. L. Ryan, and D. C. Morrison (ed.), Bacterial endotoxic lipopolysaccharides. CRC Press, Inc., Boca Raton, Fla.
|
| 8.
|
Echtenacher, B.,
L. Hültner, and D. N. Männel.
1996.
Cellular and molecular mechanisms of TNF protection in septic peritonitis.
J. Inflamm.
47:85-89.
|
| 9.
|
Eskandari, M. K.,
G. Bolgos,
C. Miller,
D. T. Nguyen,
L. E. DeForge, and D. G. Remick.
1992.
Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia.
J. Immunol.
148:2724-2730[Abstract].
|
| 10.
|
Fiedler, V. B.,
I. Loof,
E. Sander,
V. Voehringer,
C. Galanos, and M. A. Fournel.
1992.
Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys.
J. Lab. Clin. Med.
120:574-588[Medline].
|
| 11.
|
Franks, A. K.,
K. I. Kujawa, and L. J. Yaffe.
1991.
Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival.
Infect. Immun.
59:2609-2614[Abstract/Free Full Text].
|
| 12.
|
Freudenberg, M. A., and C. Galanos.
1991.
Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice.
Infect. Immun.
59:2110-2115[Abstract/Free Full Text].
|
| 13.
|
Freudenberg, M. A.,
D. Keppler, and C. Galanos.
1986.
Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin.
Infect. Immun.
51:891-895[Abstract/Free Full Text].
|
| 14.
|
Galanos, C.,
M. A. Freudenberg, and W. Reutter.
1979.
Galactosamine-induced sensitization to the lethal effects of endotoxin.
Proc. Natl. Acad. Sci. USA
76:5939-5943[Abstract/Free Full Text].
|
| 15.
|
Galanos, C.,
M. A. Freudenberg,
R. Salamao,
H. Mossman, and Y. Kumazawa.
1992.
Galactosamine-induced sensitization to the lethal effects of endotoxin, p. 75-104.
In
J. L. Ryan, and D. C. Morrison (ed.), Bacterial endotoxic lipopolysaccharides. CRC Press, Inc., Boca Raton, Fla.
|
| 16.
|
Gerard, C.,
C. Bruyns,
A. Marchant,
D. Abramowicz,
P. Vandenabeele,
A. Delvaux,
W. Fiers,
M. Goldman, and T. Velu.
1993.
Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.
J. Exp. Med.
177:547-550[Abstract/Free Full Text].
|
| 17.
|
Glauser, M. P.,
D. Heumann,
J. D. Baumgartner, and J. Cohen.
1994.
Pathogenesis and potential stratagies for prevention and treatment of septic shock: an update.
Clin. Infect. Dis.
18:S205-S216.
|
| 18.
|
Harbrecht, B. G.,
S. C. Wang,
R. L. Simmons, and T. R. Billiar.
1995.
Cyclic GMP and guanylate cyclase mediate lipopolysaccharide-induced Kupffer cell tumor necrosis factor-alpha synthesis.
J. Leukoc. Biol.
57:297-302[Abstract].
|
| 19.
|
Henricson, B. E.,
P. Y. Perera,
N. Qureshi,
K. Takayama, and S. N. Vogel.
1992.
Rhodopseudomonas sphaeroides lipid A derivatives block in vitro induction of tumor necrosis factor and endotoxin tolerance by smooth lipopolysaccharide and monophosphoryl lipid A.
Infect. Immun.
60:4285-4290[Abstract/Free Full Text].
|
| 20.
|
Hesse, D. G.,
K. J. Tracey,
Y. Fong,
K. R. Manogue,
M. A. Palladino, Jr.,
A. Cerami,
G. T. Shires, and S. F. Lowry.
1988.
Cytokine appearance in human endotoxemia and primate bacteremia.
Surg. Gynecol. Obstet.
166:147-153[Medline].
|
| 21.
|
Hill, M. R., and R. E. McCallum.
1992.
Identification of tumor necrosis factor as a transcriptional regulator of the phosphoenolpyruvate carboxykinase gene following endotoxin treatment of mice.
Infect. Immun.
60:4040-4050[Abstract/Free Full Text].
|
| 22.
|
Hodge-Dufour, J.,
P. W. Noble,
M. R. Horton,
C. Bao,
M. Wysoka,
M. D. Burdick,
R. M. Strieter,
G. Trinchieri, and E. Puré.
1997.
Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages.
J. Immunol.
159:2492-2500[Abstract/Free Full Text].
|
| 23.
|
Kumins, N. H.,
J. Hunt,
R. L. Gamelli, and J. P. Filkins.
1996.
Partial hepatectomy reduces the endotoxin-induced peak circulating level of tumor necrosis factor in rats.
Shock
5:385-388[Medline].
|
| 24.
|
Miethke, T.,
K. Duschek,
C. Wahl,
K. Heeg, and H. Wagner.
1993.
Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1.
Eur. J. Immunol.
23:1494-1500[Medline].
|
| 25.
|
Morrison, D. C.,
R. L. Danner,
C. A. Dinarello,
R. S. Munford,
C. Natanson,
M. Pollack,
J. A. Spitzer,
R. J. Ulevitch,
S. N. Vogel, and E. McSweegan.
1994.
Bacterial endotoxins and pathogenesis of Gram-negative infections: current status and future directions.
J. Endotoxin Res.
1:71-83.
|
| 26.
|
Morrison, D. C., and J. L. Ryan.
1987.
Endotoxins and disease mechanisms.
Annu. Rev. Med.
38:417-432[Medline].
|
| 27.
|
Nagaki, M.,
Y. Muto,
H. Ohnishi,
S. Yasuda,
K. Sano,
T. Naito,
T. Maeda,
T. Yamada, and H. Moriwaki.
1994.
Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B.
Gastroenterology
106:450-458[Medline].
|
| 28.
|
Natanson, C.,
W. D. Hoffman,
A. F. Suffredini,
P. Q. Eichacker, and R. L. Danner.
1994.
Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis.
Ann. Intern. Med.
120:771-787[Abstract/Free Full Text].
|
| 29.
|
Raetz, C. R.,
R. J. Ulevitch,
S. D. Wright,
C. H. Sibley,
A. Ding, and C. F. Nathan.
1991.
Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction.
FASEB J.
5:2652-2660[Abstract].
|
| 30.
|
Redl, H.,
G. Schalag,
S. Bahrami,
U. Schade,
M. Ceska, and P. Stutz.
1991.
Plasma neutrophil-activating peptide-1/interleukin-8 and neutrophil elastase in a primate bacteremia model.
J. Infect. Dis.
164:383-388[Medline].
|
| 31.
|
Reed, L. J., and H. A. Muench.
1938.
A simple method of estimating fifty percent endpoints.
Am. J. Hyg.
27:493-497.
|
| 32.
|
Remick, D.,
P. Manohar,
G. Bolgos,
J. Rodriguez,
L. Moldawer, and G. K. Wollenberg.
1995.
Blockade of tumor necrosis factor reduced lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture.
Shock
4:89-95[Medline].
|
| 33.
|
Rigato, O.,
S. Ujvari,
A. Castelo, and R. Salomao.
1996.
Tumor necrosis factor alpha (TNF- ) and sepsis: evidence for a role in host defense.
Infection
24:314-318[Medline].
|
| 34.
|
Rosenstreich, D. L.,
S. N. Vogel,
A. Jacques,
L. M. Wahl,
I. Scher, and S. E. Mergenhagen.
1978.
Differential endotoxin sensitivity of lymphocytes and macrophages from mice with an X-linked defect in B cell maturation.
J. Immunol.
121:685-690[Abstract/Free Full Text].
|
| 35.
|
Salkowski, C. A.,
R. Neta,
T. A. Wynn,
G. Strassmann,
N. van Rooijen, and S. N. Vogel.
1995.
Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radioprotection.
J. Immunol.
155:3168-3179[Abstract].
|
| 36.
|
Sánchez-Cantú, L.,
H. N. Rode,
T. J. Yun, and N. V. Christou.
1991.
Tumor necrosis factor alone does not explain the lethal effect of lipopolysaccharide.
Arch. Surg.
126:231-235[Abstract/Free Full Text].
|
| 37.
|
Shalaby, M. R.,
J. Halgunste,
O. A. Haugen,
H. Aarset,
L. Aarden, and A. Waage.
1992.
Cytokine-associated tissue injury and lethality in mice: a comparative study.
Clin. Immunol. Immunopathol.
61:69-82.
|
| 38.
|
Silverstein, R.,
M. Norimatsu, and D. C. Morrison.
1997.
Fundamental differences during Gram-positive versus Gram-negative sepsis become apparent during bacterial challenge of D-galactosamine-treated mice.
J. Endotoxin Res.
4:173-181.
|
| 39.
|
Stelter, F.,
S. Witt,
B. Furll,
R. S. Jack,
T. Hartung, and C. Schutt.
1998.
Different efficacy of soluble CD14 treatment in high- and low-dose LPS models.
Eur. J. Clin. Investig.
28:205-213[Medline].
|
| 40.
|
Tracey, K. J., and A. Cerami.
1994.
Tumor necrosis factor: a pleiotropic cytokine and therapeutic target.
Annu. Rev. Med.
45:491-503[Medline].
|
| 41.
|
Ulich, T. R.,
K. Z. Guo,
D. Remick,
J. del Castillo, and S. M. Yin.
1991.
Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6.
J. Immunol.
146:2316-2323[Abstract].
|
| 42.
|
Walley, K. R.,
N. W. Lukacs,
T. J. Standiford,
R. M. Strieter, and S. L. Kunkel.
1996.
Balance of inflammatory cytokines related to severity and mortality of murine sepsis.
Infect. Immun.
64:4733-4738[Abstract].
|
| 43.
|
Wang, P.,
Z. F. Ba, and I. H. Chaudry.
1997.
Mechanism of hepatocellular dysfunction during early sepsis. Key role of increased gene expression and release of proinflammatory cytokines tumor necrosis factor and interleukin-6.
Arch. Surg.
132:364-369[Abstract/Free Full Text].
|
| 44.
|
Zhang, H.,
J. W. Peterson,
D. W. Nielsen, and G. R. Klimpel.
1997.
Bacterial lipoprotein and lipopolysaccharide act synergistically to induce lethal shock and proinflammatory cytokine production.
J. Immunol.
159:4868-4878[Abstract].
|
| 45.
|
Zhang, X., and D. C. Morrison.
1993.
Lipopolysaccharide structure-function relationship in activation versus reprogramming of mouse peritoneal macrophages.
J. Leukoc. Biol.
54:444-450[Abstract].
|
| 46.
|
Zuckerman, S. H., and G. F. Evans.
1992.
Endotoxin tolerance: in vivo regulation of tumor necrosis factor and interleukin-1 synthesis is at the transcriptional level.
Cell Immunol.
140:513-519[Medline].
|
Infection and Immunity, November 1998, p. 5372-5378, Vol. 66, No. 11
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Satoh, M., Ando, S., Shinoda, T., Yamazaki, M.
(2008). Clearance of bacterial lipopolysaccharides and lipid A by the liver and the role of arginino-succinate synthase. Innate Immunity
14: 51-60
[Abstract]
-
Silverstein, R.
(2004). Review: D-Galactosamine lethality model: scope and limitations. Innate Immunity
10: 147-162
[Abstract]
-
Swantek, J. L., Tsen, M. F., Cobb, M. H., Thomas, J. A.
(2000). IL-1 Receptor-Associated Kinase Modulates Host Responsiveness to Endotoxin. J. Immunol.
164: 4301-4306
[Abstract]
[Full Text]
-
Luchi, M., Morrison, D. C.
(2000). Comparable Endotoxic Properties of Lipopolysaccharides Are Manifest in Diverse Clinical Isolates of Gram-Negative Bacteria. Infect. Immun.
68: 1899-1904
[Abstract]
[Full Text]
-
Silverstein, R., Wood, J. G., Xue, Q., Norimatsu, M., Horn, D. L., Morrison, D. C.
(2000). Differential Host Inflammatory Responses to Viable Versus Antibiotic-Killed Bacteria in Experimental Microbial Sepsis. Infect. Immun.
68: 2301-2308
[Abstract]
[Full Text]
-
Lopez-Urrutia, L., Alonso, A., Nieto, M. L., Bayon, Y., Orduna, A., Sanchez Crespo, M.
(2000). Lipopolysaccharides of Brucella abortus and Brucella melitensis Induce Nitric Oxide Synthesis in Rat Peritoneal Macrophages. Infect. Immun.
68: 1740-1745
[Abstract]
[Full Text]